Amarantus Bioscience Holdings Inc (AMBS)

[JJAAMMAANN]

And I thought the expectations of utilizing Eltoprazine were to decrease Levodopa-induced dyskinesia(LID) in the treatment of Parkinson's disease. If the goal is to reduce or eliminate the hyperkinetic movements associated with the disease, would AMBS actually consider licencing Dipraglurant to add to their pipeline? Seeing how the side effects are pretty awful themselves, would one rather be shaking... or nearly incapacitated and not shaking?

Results show that dipraglurant was safe and well tolerated with the most important side effects being vertigo, blurred vision, and a drunk feeling but none of these was severe.

I sure hope Dr. Keywood is being brought in for the reasons stated in the Press release...(Develop Eltoprazine and MANF), and not to continue to work on the stagnant Dipraglurant program that has been sitting idle for the past year waiting for someone to in licence and continue onto a Phase 2B.

"I am very pleased to be joining the team at Amarantus to lead the clinical development programs of Eltoprazine and MANF," said Dr. Keywood, Amarantus' newly appointed Chief Medical Officer. "Eltoprazine has an attractive profile for a number of potential central nervous system indications. We intend to focus initially on the clinical study planning for Eltoprazine in PD LID and Adult ADHD, based on the successful Phase 2a data that were previously reported in these indications."

I would be much more interested in hearing some statistics from some of the other studies then hearing about another way underdeveloped product being added to the pipeline.

Need to develop the products we have...start working towards producing capital and stop adding products to be developed by issuing more shares to pay the bills.

Can't wait to read the 10-K.....Less than a week now to get it filed....hope its good!

Of course in my Own Opinion...
Long AMBS!